Ranbaxy likely to tie-up with MNC to source Diovan APIs Diovan was the drug which was off-patented in September 2012 and Ranbaxy has a first-to-file (FTF) status over it. This means they will get six months of marketing exclusivity in the market.
RANBAXY Currently in Intraday SELL Zone . It is likely to test Support 408 / 402 / 391 . Depends upon volume And if it breaks Above 418 , Then it may surge to upperside Resistance, such as 424 / 435 / 441 . Currently RANBAXY is Trading @ 414
RANBAXY Currently in Intraday SELL Zone . It is likely to test Support 408 / 402 / 391 . Depends upon volume And if it breaks Above 418 , Then it may surge to upperside Resistance, such as 424 / 435 / 441 . Currently RANBAXY is Trading @ 414
